BioMedNewsBreaks

WednesdayOct 08, 2025 1:54 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL, NXPLW) Issues Q4 Shareholder Update Highlighting Cost Reductions, Healthcare Expansion, and Growth Across Core Channels 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, issued a shareholder update detailing operational progress and strategic initiatives for the remainder of 2025. Interim CEO Charles M. Fernandez reported that the company has implemented a comprehensive restructuring plan focused on cost reduction, operational efficiency, and growth acceleration. Recent actions include realignment of NextPlat’s healthcare management team under Progressive Care’s new Vice President of Healthcare Operations, Birute Norkute, and the identification of approximately $2 million in annualized expense savings. The company also reported significant progress across its three…

Continue Reading

WednesdayOct 08, 2025 10:35 am

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Need for Advanced 3D Imaging During Breast Cancer Awareness Month

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based technologies for more accurate breast cancer screening, diagnosis, and treatment, marked Breast Cancer Awareness Month by emphasizing the limitations of current imaging tools and the significant opportunity for its flagship IzoView Breast CT Imaging System. With more than 2.3 million new breast cancer cases reported globally each year—and over 315,000 expected in the U.S. in 2025—Izotropic underscored the urgent need for true high-resolution 3D imaging, especially for women with dense breast tissue, which affects roughly 50% of women and diminishes the accuracy of compression-based screening. As the…

Continue Reading

WednesdayOct 08, 2025 10:16 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia

Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. Conducted in collaboration with SOCRU, Ingenū, and Medicilon, the trial (ACTRN12625001083482) is now enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. “Sapu-003…

Continue Reading

WednesdayOct 08, 2025 9:55 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website. To view the full press release, visit https://ibn.fm/MQAEm About Nutriband…

Continue Reading

TuesdayOct 07, 2025 12:32 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with prior trials. Enrollment is progressing on schedule, with an update expected in Q4 2025 and a blinded interim efficacy analysis planned for 1H 2026. The FLASH2 trial builds on the Company’s earlier statistically significant Phase 3 results and additional supportive studies demonstrating HyBryte’s efficacy and…

Continue Reading

MondayOct 06, 2025 10:35 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics Inc., announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Oct. 8, 2025, at 9:30 a.m. ET. Dr. Javitt will discuss the upcoming launch of a low-dose D-Cycloserine (DCS) product shown to enhance the effectiveness of Transcranial Magnetic Stimulation (TMS) for depression, as well as the Company’s expanded clinical operations in Florida and collaborations with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD. To view the…

Continue Reading

FridayOct 03, 2025 1:45 pm

BioMedNewsBreaks — Alpha Cognition Inc. (NASDAQ: ACOG) Prices $35 Million Oversubscribed Public Offering

Alpha Cognition (NASDAQ: ACOG), a commercial-stage biopharmaceutical company focused on treatments for neurodegenerative diseases, announced the pricing of its oversubscribed underwritten public offering of 5.6 million common shares (or pre-funded warrants in lieu thereof) at $6.25 per share, for gross proceeds of approximately $35 million before expenses. The company plans to use net proceeds to accelerate commercialization of ZUNVEYL(R) (Benzgalantamine), including sales expansion, marketing, payer coverage, and reimbursement infrastructure. CEO Michael McFadden said the funding will help maximize near-term adoption while laying the foundation for long-term growth. Titan Partners Group, a division of American Capital Partners, is acting as sole…

Continue Reading

WednesdayOct 01, 2025 9:00 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing and institutional healthcare investors, also amends prior warrants to a $1.35 exercise price and extends the company’s cash runway through the end of 2026. To view the full press release, visit https://ibn.fm/7omvV About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing…

Continue Reading

TuesdaySep 30, 2025 11:15 am

BioMedNewsBreaks — Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy

  Predictive Oncology (NASDAQ: POAI) announced the pricing of two concurrent private placement transactions totaling approximately $344.4 million to support its new digital asset treasury strategy centered on ATH, the native token of the Aethir ecosystem; the deal includes a $51.7 million cash PIPE and a $292.7 million crypto PIPE involving pre-funded warrants, with proceeds earmarked for ATH acquisition, working capital, and general corporate purposes. To view the full press release, visit https://ibn.fm/8wFGz About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and…

Continue Reading

TuesdaySep 30, 2025 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization. To view the full press release, visit https://ibn.fm/Xjq13 About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business…

Continue Reading